Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

An influx of late-phase programs has prompted Genmab to reassess its bets. | An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical ...

A team of AI researchers and mathematicians affiliated with several institutions in the U.S. and the U.K. has developed a math benchmark that allows scientists to test the ability of AI systems to ...

Seaport Therapeutics (“Seaport or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the ...

CHICAGO — A real-world study of the ocular side effects of the gynecological cancer treatment mirvetuximab (Elahere) has ...

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Oct. 31, 2024 (GLOBE NEWSWIRE) -- The "Cancer Antibody Drug Conjugates market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has ...

ABBV's third-quarter 2024 earnings and sales beat estimates. The company increases the EPS guidance on encouraging product ...

AbbVie Inc. ABBV reported adjusted earnings of $3.00 per share for the third quarter of 2024, beating the Zacks Consensus Estimate of $2.92. The reported earnings also exceeded the company’s ...

AbbVie's Q3 earnings surpassed expectations with $3.00 EPS and $14.46 billion in revenue. Skyrizi and Rinvoq led growth; AbbVie also raised 2024 EPS guidance.

Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent; These Results Include an Unfavorable Impact of $0.04 ...